Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Trial ID or NCT#



recruiting iconRECRUITING


This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.

Official Title

A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers

Eligibility Criteria

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes


Farshad Moradi
Farshad Moradi
Clinical Associate Professor, Radiology - Rad/Nuclear Medicine
Kip E. Guja, MD PhD
Clinical Instructor, Radiology - Rad/Nuclear Medicine
Irina Skylar-Scott
Irina Skylar-Scott
General neurologist, Memory disorders specialist
Clinical Assistant Professor, Neurology & Neurological Sciences
Jeffrey Dunn, MD
Jeffrey Dunn, MD
Multiple sclerosis specialist, Neurologist
Clinical Professor, Neurology & Neurological Sciences

Contact us to find out if this trial is right for you.


Caroline Huang
(650) 723-0341